I am excited to announce that the NCH Rooney Heart Institute has achieved a significant milestone with the successful completion of a clinical trial evaluating the Affera™ Mapping and Ablation System, featuring the Sphere-9™ Catheter.
As one of only two sites in Florida to offer this innovative technology, NCH continues to lead the way in advancing cardiac care.
Designed to enhance the treatment of atrial fibrillation (AF) and other complex cardiac arrhythmias, the Affera system integrates high-density mapping with dual-energy ablation capabilities. By offering both pulsed field (PF) and radiofrequency (RF) energies, the platform allows for precise, patient-specific treatment that improves outcomes and procedural efficiency.
Led by Dinesh Sharma, MD, the trial demonstrated the system’s safety and effectiveness, representing a major advancement in electrophysiology care. The Affera system’s ability to seamlessly combine mapping and dual-energy ablation has proven to be a transformative tool for treating patients with persistent AF. The results showed notable improvements in procedural efficiency and faster recovery times, further solidifying NCH’s commitment to providing cutting-edge cardiovascular care…